CA
NZ
UK
AU
IND
US
The sale of 5,246 common shares by AeroVironment’s chief executive generated immediate market attention because the transaction was priced at $144.58 per share, exactly matching the closing price on July 10 2026. The insider move left Nawabi with an estimated 162,200 shares, representing roughly …
Boeing's chief executive, Kelly Ortberg, told investors that the aerospace giant must first shore up its balance sheet before it can commit capital to a next‑generation jet. The company aims to be ready to fund the program later this decade, a timeline that pushes …
Advanced Biomed (NASDAQ: ADVB) shares rose 32% in pre-market trading after the company disclosed via an SEC filing that it has terminated its June 2025 stock purchase agreement with Helena Global Investment Opportunities I.
Clariant’s stock decline reflects broader turbulence in the chemical sector, where weak demand and rising input costs are squeezing margins. The move follows a wave of caution among investors, who are reassessing exposure to industrials amid signs of slowing global manufacturing activity. The shift …
BioVie Inc. (NASDAQ: BIVI) shares fell 22% in pre-market trading after the company submitted a registration statement to the SEC on July 17, 2026, for a proposed sale of Class A common stock and warrants, with specific pricing and volume details yet to be …
Daktronics has reset its executive compensation framework, tying annual and long-term incentives to specific 2027 financial targets as the industrial display manufacturer navigates a period of flat share performance. The board’s approval of the 2027 Compensation Program marks a structural shift in how the …
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares were flat in pre-market trading after the company entered into a confidential separation agreement with Chief Medical Officer Dr. James J. Ferguson III following his voluntary resignation notice submitted on July 7, 2026.
European chemical manufacturers released their second‑quarter results, revealing that a trio of major players elevated full‑year profit outlooks while the broader sector confronts mixed signals on demand. The earnings batch arrived as conflict‑related supply shocks in the Middle East temporarily lifted product prices, offering …
Immunome, Inc. (NASDAQ: IMNM) shares were flat in pre-market trading after the company said the initial participant has received a dose in the Phase 1 first-in-human clinical trial evaluating IM-3050, a novel radioligand therapy.
Glucotrack, Inc. (NASDAQ: GCTK) shares fell 12% in pre-market trading after the company finalized a $4.45 million senior secured convertible bridge loan, closed in tandem with a stock-for-stock merger with Lōkahi Therapeutics.
Please wait processing your request...